Navigation Links
Research helps clarify how obesity leads to type 2 diabetes, cancer
Date:6/5/2014

New findings about the biological links between obesity, insulin resistance and type 2 diabetes may also shed light on the connection between obesity and cancer, says a scientist at The University of Texas at Dallas.

In a study published online June 5 in the journal Cell, UT Dallas' Dr. Jung-whan (Jay) Kim and colleagues at the University of California, San Diego found that a protein called HIF-1 alpha plays a key role in the development of insulin resistance and type 2 diabetes in obese mice.

The researchers genetically engineered mice to lack the HIF-1 alpha protein within the animals' fat cells, or adipocytes. The animals still made HIF-1 alpha in other types of cells and tissues in their bodies. Although the mice became obese when fed a high-fat diet, they did not develop insulin resistance and diabetes to near the extent that genetically normal, obese mice did.

"There is clearly a greater chance among the obese human population to develop insulin resistance and diabetes. We still don't know the exact mechanism, but now we know that HIF-1 alpha is very active in the pathogenesis of these diseases from obesity," said Kim, a co-lead author of the study who conducted the research while a postdoctoral researcher at UC San Diego and the Salk Institute for Biological Studies. He joined the UT Dallas faculty as an assistant professor of molecular and cell biology in 2013.

Kim said the findings about HIF-1, which stands for hypoxia inducible factor-1, are significant not only for their possible application to fighting insulin resistance and diabetes, but also cancer. Here's why:

Cells in the body normally consume oxygen to produce energy. But if oxygen levels decrease, for example during strenuous exercise or at high altitudes, cells enter a condition called hypoxia, or low oxygen. With oxygen in short supply, cells switch their metabolism. Instead of energy, the cells produce reactive oxygen species, which are molecules that can damage or kill cells. To help mitigate the damage, hypoxic cells activate HIF-1 alpha, which in turn shuts down the production of reactive oxygen species and signals inflammatory cells to migrate to the hypoxic areas.

"Organisms need to be able to temporarily adapt to the stress of hypoxic conditions until the situation changes, so when inflammatory cells see this kind of signal, they come to the hypoxic area to do their normal job, which is to basically eat damaged cells," Kim said.

In obesity, however, fat cells are in a chronic state of hypoxia.

"If you look at adipose, or fat tissue, in the obese, there is massive and chronic inflammation," he said. "It's a defense mechanism. The inflammatory cells are really good guys, but as obesity persists, inflammation becomes chronic.

"HIF-1 alpha is important for hypoxia adaptation, but it's constantly activated in the obese, and that's where it turns bad," Kim said. "In the obese, HIF-1 is aberrantly and chronically elevated and is the master regulator of ominous chronic inflammation."

To study the effect HIF-1 alpha might have on the development of insulin resistance and diabetes, Kim and his colleagues used genetic engineering techniques to completely remove, or "knock out" HIF-1 alpha from adipose tissue in obese mice.

"Once we knocked out HIF-1, everything got better," he said. "The fat cells survived and the mice remained obese, but we saw less inflammation in the fat tissue. These mice responded better to insulin than their normal counterparts, which means insulin sensitivity was improved and glucose tolerance was improved."

Kim said several pharmaceutical companies are developing HIF-1 alpha inhibitors to block the protein from functioning, which might one day result in medications to treat type 2 diabetes and insulin resistance in obese people. But the primary reason the pharmaceutical industry is already investigating HIF-1 alpha inhibitors is cancer.

"Tumor cells grow really fast, but the blood vessels that feed them oxygen cannot grow fast enough, so tumor cells become hypoxic," Kim explained. "The tumor cells have to develop some sort of mechanism to survive under hypoxic stress, and that's HIF-1 alpha.

"If you can inhibit HIF-1 alpha in a tumor cell, you can kill the cell, and that's why pharmaceutical companies are interested in HIF-1 inhibitors."

Kim said one motivation for the Cell study was to gain a better understanding of the links between obesity and cancer.

"There is a clear correlation between the two, but it's not clear why obese people have a greater chance of developing certain cancers," he said. "If you look at breast cancer, the glands that produce milk are completely surrounded by fat cells.

"Tumor tissue is hypoxic. Obese tissue is hypoxic. HIF-1 alpha is important in both conditions. I'm very motivated to study the interaction between breast cancer cells and fat cells."


'/>"/>

Contact: Amanda Siegfried
amanda.siegfried@utdallas.edu
972-883-4335
University of Texas at Dallas
Source:Eurekalert

Related medicine news :

1. NIDA review summarizes research on marijuanas negative health effects
2. UO researchers use rhythmic brain activity to track memories in progress
3. FAPESP announces the SPRINT -- Sao Paulo Researchers in International Collaboration
4. A new approach to Alzheimers disease research
5. UCLA researchers identify new gene involved in Parkinsons disease
6. Researching how residential environment impacts preterm delivery in African-Americans
7. Notre Dame receives Gates grant for groundbreaking research in global heal
8. Moffitt researchers develop process to help personalize treatment for lung cancer patients
9. NIH task force proposes standards for research on chronic low back pain
10. Researchers to expand child exploitation web-crawler
11. Health Data Exploration network to spur research using personal health data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... 29, 2016 , ... For those who skip meals occasionally (which is pretty ... among the many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya ... Water® radio show. Bonny and Lawrence noted that because proper nutrition, including water, provides ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with Ed Begley Jr., ... episode, airing third quarter 2016 via Discovery Channel. Dates and show times TBA. ... Products, located in Greenwood, Wisconsin applies product research and development and continuous technological ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE Media Group ... patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci ... Extraordinary Healer® for Oncology Nursing , which honors nurses who have dedicated their ...
(Date:4/29/2016)... Rafael, CA (PRWEB) , ... April 29, 2016 , ... ... week long softball camp from July 24th – 27th for girls aged 10-18. All ... camp is held at the beautiful Clark V. Whited Complex, one of the finest ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... of oral drug delivery systems, announced today that the Company ... Joseph Gunnar & Co. LLC, taking place on ... Nadav Kidron , CEO of Oramed, will present a ...   PIONEERS 2016, presented by Joseph Gunnar ...
(Date:4/27/2016)... Inc. (Nasdaq: HOLX ) announced today ... quarter ended March 26, 2016.  GAAP diluted earnings ... non-GAAP diluted EPS of $0.47 increased 14.6%.  Revenue ... basis, and 6.3% on a constant currency basis.  ... highlighted by 14.6% growth in non-GAAP EPS," said ...
Breaking Medicine Technology: